XOPTIBAZE Trademark

Trademark Overview

On Friday, October 16, 2020, a trademark application was filed for XOPTIBAZE with the United States Patent and Trademark Office. The USPTO has given the XOPTIBAZE trademark a serial number of 90260227. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, May 31, 2024. This trademark is owned by Eli Lilly and Company. The XOPTIBAZE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetes
xoptibaze

General Information

Serial Number90260227
Word MarkXOPTIBAZE
Filing DateFriday, October 16, 2020
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, May 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 13, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetes
Pseudo MarkX OPTIC BASE

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, May 31, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events

Event DateEvent Description
Tuesday, October 20, 2020NEW APPLICATION ENTERED
Sunday, December 6, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, March 6, 2021ASSIGNED TO EXAMINER
Tuesday, March 9, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 13, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, March 24, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 13, 2021PUBLISHED FOR OPPOSITION
Tuesday, June 8, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, October 7, 2021SOU EXTENSION 1 GRANTED
Thursday, October 7, 2021SOU TEAS EXTENSION RECEIVED
Thursday, October 7, 2021SOU EXTENSION 1 FILED
Wednesday, May 18, 2022SOU EXTENSION 2 GRANTED
Saturday, October 9, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 18, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, May 18, 2022SOU EXTENSION 2 FILED
Wednesday, October 26, 2022ASSIGNED TO EXAMINER
Friday, May 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 9, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 9, 2022SOU EXTENSION 3 FILED
Wednesday, November 9, 2022SOU EXTENSION 3 GRANTED
Friday, May 12, 2023SOU TEAS EXTENSION RECEIVED
Friday, May 12, 2023SOU EXTENSION 4 FILED
Friday, May 12, 2023SOU EXTENSION 4 GRANTED
Friday, November 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 8, 2023SOU EXTENSION 5 FILED
Thursday, November 16, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, May 16, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 8, 2023SOU TEAS EXTENSION RECEIVED
Thursday, November 16, 2023SOU EXTENSION 5 GRANTED
Friday, November 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 30, 2024TEAS EXPRESS ABANDONMENT RECEIVED
Friday, May 31, 2024ABANDONMENT - AFTER PUBLICATION
Friday, May 31, 2024ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION

Related Keywords

xoptibaze pharmaceutical preparations diabetes namely treatment